Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.45 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22875582 | 0.83 | POLB (0.65) | EHMT1POLBENPP1P2RY1 | |
| SCHEMBL9386385 | 0.83 | CYP3A4 (0.40) | BCHECYP3A4CYP2D6RXFP1EHMT1 | |
| SCHEMBL22875451 | 0.83 | POLB (0.47) | POLB | |
| SCHEMBL21894145 | 0.82 | BCHE (0.53) | BCHEPOLBENPP1P2RY1 | |
| SCHEMBL19636108 | 0.82 | BCHE (0.53) | BCHEPOLBENPP1P2RY1 | |
| SCHEMBL21251592 | 0.82 | BCHE (0.53) | BCHEPOLBENPP1P2RY1 | |
| SCHEMBL20225051 | 0.82 | P2RY1 (0.62) | POLBENPP1P2RY1 | |
| SCHEMBL18837728 | 0.82 | P2RY1 (0.62) | POLBENPP1P2RY1 | |
| SCHEMBL20959779 | 0.82 | P2RY1 (0.62) | POLBENPP1P2RY1 | |
| SCHEMBL20225019 | 0.82 | P2RY1 (0.62) | POLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210007999-A1 | NANOPARTICLE COMPOSITIONS | JANUARY THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210007999-A1 | NANOPARTICLE COMPOSITIONS | PNP, NTPCR, TYMP | BCHE 2333/4885FGFR1 3890/4885CYP3A4 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.